Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

Published:2017-12-06 Issue:2 Volume:124 Page:325-334
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Roboz Gail J.¹,Kantarjian Hagop M.²^ORCID,Yee Karen W. L.³,Kropf Patricia L.⁴,O'Connell Casey L.⁵,Griffiths Elizabeth A.⁶,Stock Wendy⁷,Daver Naval G.²^ORCID,Jabbour Elias²^ORCID,Ritchie Ellen K.¹,Walsh Katherine J.⁸,Rizzieri David⁹,Lunin Scott D.¹⁰,Curio Tania¹,Chung Woonbok¹¹,Hao Yong¹²,Lowder James N.¹²^ORCID,Azab Mohammad¹²,Issa Jean-Pierre J.¹¹

Affiliation:

1. Weill Cornell Medicine, NewYork-Presbyterian Hospital; New York New York

2. The University of Texas MD Anderson Cancer Center; Houston Texas

3. Princess Margaret Cancer Centre; Toronto Ontario Canada

4. Fox Chase Cancer Center; Philadelphia Pennsylvania

5. Keck School of Medicine; University of Southern California; Los Angeles California

6. Roswell Park Cancer Institute; Buffalo New York

7. University of Chicago; Chicago Illinois

8. Ohio State University; Columbus Ohio

9. Duke University Medical Center; Durham North Carolina

10. Florida Cancer Specialist and Research Institute; Fort Myers Florida

11. Fels Institute for Cancer Research and Molecular Biology; Temple University; Philadelphia Pennsylvania

12. Astex Pharmaceuticals; Pleasanton California

Funder

Stand Up To Cancer

Astex Pharmaceuticals, Inc.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference22 articles.

1. Salvage therapy for relapsed or refractory acute myeloid leukemia;Mangan;Ther Adv Hematol.,2011

2. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia;Ramos;J Clin Med.,2015

3. International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia;Roboz;J Clin Oncol.,2014

4. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies;Issa;Blood.,2004

5. Multicenter, randomized, #open |label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia;Kantarjian;J Clin Oncol.,2012

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic-modifying agents: the potential game changers in the treatment of hematologic malignancies;Critical Reviews in Oncology/Hematology;2024-09

2. Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial;Blood Advances;2024-04-23

3. Glasdigib fails to slay the hedgehog in pivotal AML trials;Leukemia;2023-10-10

4. Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study;Blood Advances;2023-08-28

5. Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating Agents;Epigenomes;2023-07-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3